Novartis is to spin off Sandoz, its generics business, into a separately incorporated Swiss company by the second half of 2023 in order to focus on proprietary medicine development. The decision, announced on 25 August, follows a year-long strategic review that included the options of retaining Sandoz as an autonomous business unit within the group, or divesting it.
